{
 "name": "富禾生醫",
 "slug": "tw-7773",
 "aliases": [
  "富禾生醫股份有限公司",
  "FullHope",
  "7773"
 ],
 "ticker": "7773",
 "industry": "生技醫療業",
 "website": "www.fhb.com.tw",
 "summary": "富禾生醫（7773）是興櫃的生技醫療類股公司，2012 年成立，2024 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "富禾生醫股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "FullHope",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2024-09-26",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2012-12-24",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "趙毅",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "李建謀",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 399112090,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "www.fhb.com.tw",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：EBaT8（NK／T細胞淋巴瘤）",
   "value": "NK／T細胞淋巴瘤｜研發階段（R&D）｜地區未揭露",
   "unit": "",
   "as_of": "2024-09-25",
   "source": "https://mopsov.twse.com.tw/nas/STR/777320240925M001.pdf",
   "note": "2024-09-25法說會PDF第46頁圖表，箭頭位於研發端、未達臨床階段；地區未揭露。圖表已渲染核讀，未以檔案文字萃取結果猜讀。"
  },
  {
   "claim": "管線：HPaT8（口咽癌）",
   "value": "口咽癌｜研發階段（R&D）｜地區未揭露",
   "unit": "",
   "as_of": "2024-09-25",
   "source": "https://mopsov.twse.com.tw/nas/STR/777320240925M001.pdf",
   "note": "2024-09-25法說會PDF第46頁圖表，箭頭位於研發端、未達臨床階段；地區未揭露。圖表已渲染核讀，未以檔案文字萃取結果猜讀。"
  },
  {
   "claim": "管線：Phyduxon-T衍生外泌體（帕金森氏症／阿茲海默症／失智症）",
   "value": "帕金森氏症／阿茲海默症／失智症｜研發階段（R&D）｜地區未揭露",
   "unit": "",
   "as_of": "2024-09-25",
   "source": "https://mopsov.twse.com.tw/nas/STR/777320240925M001.pdf",
   "note": "2024-09-25法說會PDF第47頁圖表，箭頭位於研發端、未達臨床階段；地區未揭露。圖表已渲染核讀，未以檔案文字萃取結果猜讀。"
  },
  {
   "claim": "管線：Phyduxon-T衍生外泌體（肌少症／肌肉萎縮／心肌梗塞）",
   "value": "肌少症／肌肉萎縮／心肌梗塞｜研發階段（R&D）｜地區未揭露",
   "unit": "",
   "as_of": "2024-09-25",
   "source": "https://mopsov.twse.com.tw/nas/STR/777320240925M001.pdf",
   "note": "2024-09-25法說會PDF第47頁圖表，箭頭位於研發端、未達臨床階段；地區未揭露。圖表已渲染核讀，未以檔案文字萃取結果猜讀。"
  },
  {
   "claim": "管線：Phyduxon-T衍生外泌體（癌症治療）",
   "value": "癌症治療｜研發階段（R&D）｜地區未揭露",
   "unit": "",
   "as_of": "2024-09-25",
   "source": "https://mopsov.twse.com.tw/nas/STR/777320240925M001.pdf",
   "note": "2024-09-25法說會PDF第47頁圖表，箭頭位於研發端、未達臨床階段；地區未揭露。圖表已渲染核讀，未以檔案文字萃取結果猜讀。"
  },
  {
   "claim": "管線：Phyduxon-T衍生外泌體（醫美應用）",
   "value": "醫美應用｜研發階段（R&D）｜地區未揭露",
   "unit": "",
   "as_of": "2024-09-25",
   "source": "https://mopsov.twse.com.tw/nas/STR/777320240925M001.pdf",
   "note": "2024-09-25法說會PDF第47頁圖表，箭頭位於研發端、未達臨床階段；地區未揭露。圖表已渲染核讀，未以檔案文字萃取結果猜讀。"
  },
  {
   "claim": "管線：EBaT8（EBV相關鼻咽癌）",
   "value": "EBV相關鼻咽癌｜TFDA准予執行臨床第一／二a期｜台灣",
   "unit": "",
   "as_of": "2026-04-09",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "發言日期：2026-04-09 17:15:02；主旨：本公司研發之利用自體培養之EB病毒專一性毒殺T細胞對鼻咽癌病患所進行之免疫療法「EBaT8」，獲台灣衛生福利部食品藥物管理署（TFDA）核准進行第一跨二a期臨床試驗。；公司代號7773；民國115年全年度；序號1。試驗計畫FHBEBAT820251219；新案重新獲准，未把2025年終止／不受理舊案寫成持續執行，未捏造完成日期。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-7773.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}